First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma (RILOMET-1)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01697072 |
Recruitment Status :
Terminated
(All Amgen sponsored AMG102 clinical studies were terminated following a pre-planned Data Monitoring Committee safety review of study 20070622.)
First Posted : October 2, 2012
Last Update Posted : February 9, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Gastric Cancer | Drug: Rilotumumab Other: Placebo Drug: Epirubicin Drug: Cisplatin Drug: Capecitabine | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 609 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Care Provider, Investigator) |
Primary Purpose: | Treatment |
Official Title: | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Rilotumumab (AMG102) With Epirubicin, Cisplatin, and Capecitabine (ECX) as First-line Therapy in Advanced MET-Positive Gastric or Gastroesophageal Junction Adenocarcinoma |
Study Start Date : | October 2012 |
Actual Primary Completion Date : | November 2014 |
Actual Study Completion Date : | August 2015 |
Arm | Intervention/treatment |
---|---|
Experimental: Rilotumumab
Rilotumumab (15 mg/kg, IV every 21 days) plus Epirubicin, Cisplatin and Capecitabine (ECX)
|
Drug: Rilotumumab
Rilotumumab is a fully human monoclonal antibody immunoglobulin G, type 2 (IgG2) against human hepatocyte growth factor/scatter factor (HGF/SF) that blocks binding of HGF/SF to its receptor MET, inhibiting HGF/MET-driven activities in cells.
Other Name: AMG102 Drug: Epirubicin Epirubicin is an anthracycline cytotoxic agent.
Other Names:
Drug: Cisplatin Cisplatin is a non-cell cycle specific chemotherapeutic agent.
Other Names:
Drug: Capecitabine Capecitabine is an oral fluoropyrimidine.
Other Name: Xeloda |
Placebo Comparator: Placebo
Rilotumumab-placebo (15 mg/kg, IV every 21 days) plus Epirubicin, Cisplatin and Capecitabine (ECX)
|
Other: Placebo
Placebo
Other Name: sterile protein-free solution Drug: Epirubicin Epirubicin is an anthracycline cytotoxic agent.
Other Names:
Drug: Cisplatin Cisplatin is a non-cell cycle specific chemotherapeutic agent.
Other Names:
Drug: Capecitabine Capecitabine is an oral fluoropyrimidine.
Other Name: Xeloda |
- Overall Survival [ Time Frame: 3 years ]To determine if the treatment of rilotumumab in combination with ECX significantly improves overall survival in subjects with unresectable locally advanced or metastatic MET positive gastric or GEJ cancer
- PFS [ Time Frame: 3 years ]Progression Free Survival (PFS)
- TTP [ Time Frame: 3 years ]Time to Progression (TTP)
- ORR [ Time Frame: 3 years ]Objective Response Rate (ORR)
- DCR [ Time Frame: 3 years ]Disease Control Rate (DCR)
- TTR [ Time Frame: 3 years ]Time to Response (TTR)
- Safety [ Time Frame: 3 years ]
- Immunogenicity [ Time Frame: 3 years ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 99 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Key Inclusion Criteria:
- Pathologically confirmed unresectable locally advanced or metastatic gastric or GEJ adenocarcinoma •Eastern Cooperative Oncology Group (ECOG) performance status (0 or 1)
- Tumor MET-positive by immunohistochemistry (IHC)
- Evaluable (measurable or non-measurable) disease by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria
Key exclusion criteria:
- Human Epidermal Growth Factor Receptor 2 (HER2) -overexpressing locally advanced or metastatic gastric or GEJ adenocarcinoma •Previous systemic therapy for locally advanced or metastatic gastric or GEJ adenocarcinoma
- Less than 6 months have elapsed from completion of prior neoadjuvant or adjuvant chemotherapy or chemoradiotherapy to randomization
- Previous treatment with anthracyclines must not exceed total cumulative dose of epirubicin of 400 mg/m2
- Squamous cell histology
- Left ventricular ejection fraction (LVEF) < 50%
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01697072
Study Director: | MD | Amgen |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Amgen |
ClinicalTrials.gov Identifier: | NCT01697072 |
Other Study ID Numbers: |
20070622 2011-004923-11 ( EudraCT Number ) |
First Posted: | October 2, 2012 Key Record Dates |
Last Update Posted: | February 9, 2016 |
Last Verified: | January 2016 |
Gastric Cancer First Line Treatment Gastroesophageal Junction (GEJ) Gastroesophageal Junction Cancer (GEJ) GEJ Cancer |
Adenocarcinoma Stomach Neoplasms Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Digestive System Diseases Gastrointestinal Diseases Stomach Diseases Cisplatin |
Capecitabine Epirubicin Rilotumumab Antineoplastic Agents Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action Antibiotics, Antineoplastic Topoisomerase II Inhibitors Topoisomerase Inhibitors Enzyme Inhibitors Antineoplastic Agents, Immunological |